Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
about
Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewThe role of aflibercept in the management of diabetic macular edemaDevelopment of gene and stem cell therapy for ocular neurodegenerationEvaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab.Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration.Short-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation.Intravitreal Aflibercept Outcomes in Patients with Persistent Macular Exudate Previously Treated with Bevacizumab and/or Ranibizumab for Neovascular Age-Related Macular DegenerationProfile of conbercept in the treatment of neovascular age-related macular degeneration.Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Foveal structure during the induction phase of anti-vascular endothelial growth factor therapy for occult choroidal neovascularization in age-related macular degeneration.A Meta-Analysis of Studies Evaluating Visual and Anatomical Outcomes in Patients with Treatment Resistant Neovascular Age-Related Macular Degeneration following Switching to Treatment with AfliberceptOne-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement.Fixed bimonthly aflibercept in naïve and switched neovascular age-related macular degeneration patients: one year outcomesSwitching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis.Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab.Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedside.Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.The role of pharmacogenetics and advances in gene therapy in the treatment of diabetic retinopathy.The role of Aflibercept in the management of age-related macular degeneration.Leber's congenital amaurosis and the role of gene therapy in congenital retinal disordersAflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapy.Response of eyes with age-related macular degeneration to anti-VEGF drugs and implications for therapy planningHigh-frequency aflibercept injections in persistent neovascular age-related macular degeneration.Clinical outcomes of switching to aflibercept using a pro re nata treatment regimen in patients with neovascular age-related macular degeneration who incompletely responded to ranibizumab.VISUAL ACUITY IMPROVEMENT WHEN SWITCHING FROM RANIBIZUMAB TO AFLIBERCEPT IS NOT SUSTAINED.Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study.[Anti-VEGF therapy for neovascular age-related macular degeneration -therapeutic strategies: statement of the German Ophthalmological Society, the German Retina Society and the Professional Association of Ophthalmologists in Germany - November 2014]Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment
P2860
Q26744068-664530B1-8225-4F43-AD0F-CA7986EB9A77Q26798348-926D3EE6-D947-43CE-B52B-80C832797408Q28081549-B2CBED60-A7FC-4D0C-B9F6-58684B22102BQ33596886-AD9636D3-68B9-4224-96A0-71992E429D75Q33661457-BBE83AAE-31C7-4888-AA2D-9248DC2BC42EQ33846379-3B92AAA0-3563-48F9-BDE6-BCB99EB81094Q34645786-98F77FB8-8C1E-47CA-B410-8733607065ECQ35541714-C4E12411-B289-4ED1-9A78-25F6C3FEB87DQ35669341-5AFBD73C-5FCC-434D-B3C4-BE6B51CBEC48Q36048855-07F9B9CB-7EAC-4EA2-9E00-24A326ADBD55Q36200924-387AC607-1A77-4CB6-8B38-8E7F46884B01Q36265220-36856285-99DD-4B82-AC53-BA099AB986E0Q36706461-937CF877-5082-4412-A64F-1D279158368FQ36955686-653648D8-0059-4DE6-A5D4-8537C0C57F1FQ37188120-29AF0EEC-0253-4616-BC76-536C9D59D73AQ37582768-20F438AB-FA12-43C2-9229-8DE5D7E3F71DQ37714528-2DB7C033-44B9-466E-908B-B3688B2244C9Q38266022-358C554D-1C19-4244-850B-7CE2E13C697CQ38528148-16D45B8E-7ABA-46BE-973A-48A2A6E251AFQ38582381-5911AFF0-E0EA-42B9-8F3A-D93A4F6F7880Q38710512-BE57A5B5-1B12-4D41-A578-B06C5F62AE41Q38777050-54434837-DC64-42B3-A76C-B494B478968AQ39230754-21537797-CF54-491D-9876-CB2819AEC2BFQ41765288-15F09FD2-B306-42FA-9119-416B37918382Q42289631-4ED5D79E-1077-48A3-B1D1-99C9482707E8Q46279318-36A74F49-1DC8-4E03-BAE0-063E42EC0661Q48520571-1CE34AD4-3623-40D4-94A2-A526C58E4DF0Q50730097-DDBE6483-BA63-4134-B4D8-397A4EEDC755Q51133647-2FC5A21A-BAD8-4864-AC73-A1071604FB90Q55066350-7399D510-2D90-47E4-B472-38701472341AQ57491329-C52BC17E-A0BD-4093-8A87-C15C63EEC34B
P2860
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@ast
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@en
type
label
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@ast
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@en
prefLabel
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@ast
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@en
P2093
P2860
P1476
Aflibercept treatment for pati ...... izumab injections (TURF trial)
@en
P2093
Charles C Wykoff
Daniel E Croft
David M Brown
Maria E Maldonado
P2860
P304
P356
10.1136/BJOPHTHALMOL-2013-304736
P407
P577
2014-02-11T00:00:00Z